CVKD — Cadrenal Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Cadrenal Therapeutics Receives Legal Opinion From Blank Rome LLP On Validity Of Share Offering
Brief: Cadrenal Boosts Anticoagulation Pipeline With Acquisition Of eXIthera’s Factor XIa Inhibitor Portfolio
Cadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cadrenal Therapeutics Announces Clinical Trial Initiation Plans For Tecarfarin In Patients With End-Stage Kidney Disease (Eskd) Transitioning To Dialysis
Cadrenal Therapeutics Inc expected to post a loss of $1.60 a share - Earnings Preview
Cadrenal Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Cadrenal Therapeutics Inc expected to post a loss of $1.64 a share - Earnings Preview
Brief: Cadrenal Therapeutics Inc - Files Prospectus Supplement For $2.17 Million ATM Offering
Brief: Cadrenal Therapeutics Announces Collaboration Agreement With Abbott
Brief: Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
Brief: Cadrenal Therapeutics Receives US FDA Orphan Drug Designation For Tecarfarin
Brief: Cadrenal Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Cadrenal Therapeutics Appoints Jeff Cole As Chief Operating Officer In Advance Of Tecarfarin Phase 3 Pivotal Trial
Brief: Cadrenal Therapeutics Engages The Sage Group To Advance Tecarfarin's Late-Stage Development And Commercialization
Brief: Cadrenal Therapeutics Inc Says On Sept 6, Co Got Letter From Nasdaq Stating That Co Was Not In Compliance With Nasdaq Listing Rule
Brief: Cadrenal Therapeutics Appoints Robert Lisicki To Board
Brief: Cadrenal Therapeutics Files For Resale Of Up To 8.85 Mln Shares By Selling Stockholders
Brief: Cadrenal Therapeutics Announces Closing Of $7.5 Mln Private Placement Priced At-The-Market Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Cryoport, cybersecurity firms, China ADRs